Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids - Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP.
BACKGROUND: Untreated opioid use disorder (OUD) affects the care of HIV/HCV co-infected people who inject opioids. Despite active injection opioid use, there is evidence of increasing engagement in HIV care and adherence to HIV medications among HIV/HCV co... (Source: SafetyLit)
Source: SafetyLit - May 17, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptions
British drugmaker Indivior Plc lost nearly three-quarters of its share value on Wednesday and former parent Reckitt Benckiser also fell following U.S. criminal charges accusing Indivior of illegally increasing prescriptions for its opioid addiction treatment Suboxone. (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

DOJ charges UK drugmaker with Suboxone fraud
Federal prosecutors with the Department of Justice have indicted Indivior for what they call a multibillion-dollar scheme to ratchet up sales of an opioid addiction treatment. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 10, 2019 Category: Pharmaceuticals Source Type: news

Anti-opioid addiction drug maker charged with fraud
Federal prosecutors in Virginia say the company that makes a Suboxone strips to curb opioid addiction has been lying for years about the relative safety of its product (Source: ABC News: Health)
Source: ABC News: Health - April 10, 2019 Category: Consumer Health News Tags: Health Source Type: news

Indivior shares tank after U.S. indictment for illegal marketing
Shares of Indivior Plc sank 44 percent on Wednesday after the U.S. Justice Department accused the British drugmaker of illegally boosting prescriptions for the film version of its blockbuster opioid addiction treatment Suboxone. (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. indicts Indivior over Suboxone opioid treatment marketing
The U.S. Justice Department announced on Tuesday the indictment of Indivior Plc and a subsidiary on charges they engaged in an illegal scheme to boost prescriptions of the film version of its opioid addiction treatment Suboxone. (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

New Buprenorphine and Naloxone Sublingual Film Indicated for The Treatment of Opioid Dependence
FDA approved Buprenorphine and Naloxone Sublingual film are available in 8 mg/2 mg and 12 mg/3 mg The prescription is limited to healthcare providers who meet certain qualifying requirements Should be used as part of a complete treatment plan to include counseling and psychosocial supportThis story is related to the following:Medicinal, Pharmaceutical& Nutraceutical Tablets (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - February 25, 2019 Category: Medical Devices Source Type: news

Mylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
HERTFORDSHIRE, England and PITTSBURGH, Feb. 22, 2019 -- (Healthcare Sales & Marketing Network) -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 m... Biopharmaceuticals, Drug Delivery, Generics, Product Launch Mylan, Buprenorphine, Naloxone, Suboxone, Sublingual (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2019 Category: Pharmaceuticals Source Type: news

Mylan launches generic sublingual film for opioid dependence
Mylan (NSDQ:MYL) said today that it launched its buprenorphine and naloxone sublingual film as a generic of Indivior‘s (LON:INDV) Suboxone sublingual film. The product is indicated for the treatment of opioid dependence. The therapy should be used alongside counseling and psychosocial support for people living with opioid dependence, according to Mylan. Get the full story at our sister site, Drug Delivery Business News. The post Mylan launches generic sublingual film for opioid dependence appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 22, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Featured Pharmaceuticals Wall Street Beat Dr. Reddy's Laboratories indivior Mylan Source Type: news

Indivior launches generic version of its Suboxone opioid drug
British drugmaker Indivior Plc said on Wednesday it had launched a copycat version of its blockbuster opioid addiction drug Suboxone in the United States, just one day after a court decision cleared the way for its rivals to market generic versions of it. (Source: Reuters: Health)
Source: Reuters: Health - February 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. top court rejects bid to block Indivior opioid drug copycat
The U.S. Supreme Court dealt a blow to Indivior Plc on Tuesday, clearing the way for a copycat version of the British pharmaceutical firm's lucrative opioid addiction treatment Suboxone Film in a victory for India-based generic drug maker Dr. Reddy's Laboratories. (Source: Reuters: Health)
Source: Reuters: Health - February 19, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Overdose patients at Vancouver hospital to get take-home opioid medication
Touted as a first for Canadian emergency departments, physicians at St. Paul's Hospital in Vancouver will send overdose victims home with enough Suboxone for three days of treatment. (Source: CBC | Health)
Source: CBC | Health - February 7, 2019 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news

'I feel normal': health officials eye injectable opioid addiction treatment
Sublocade, an injectable alternative to Suboxone, has been approved by Health Canada after a successful run in the U.S. The treatment is administered once a month and is highly touted by many American physicians. (Source: CBC | Health)
Source: CBC | Health - January 17, 2019 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news

Health officials eye injectable addiction treatment that could 'turn the tide of the opioid epidemic'
Sublocade, an injectable alternative to Suboxone, has been approved by Health Canada after a successful run in the U.S. The treatment is administered once a month and is highly touted by many American physicians. (Source: CBC | Health)
Source: CBC | Health - January 17, 2019 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news

U.S. doctors have a new opioid addiction treatment in their arsenal — it could be here next
Sublocade, a monthly injectable alternative to the widely used opioid treatment Suboxone, has been approved by Health Canada after a small but so far successful run in the U.S. (Source: CBC | Health)
Source: CBC | Health - January 17, 2019 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news

UPMC Health Plan training doctors to treat opioid-abuse disorder
Suboxone is a narcotic that can be used to treat addiction to narcotic pain relievers. But being able to prescribe the medication requires a waiver from the Drug Enforcement Agency. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 21, 2018 Category: American Health Authors: Paul J. Gough Source Type: news

Indivior Plans Cheaper Opioid Addiction Drug if Rivals Launch Copycats Indivior Plans Cheaper Opioid Addiction Drug if Rivals Launch Copycats
Indivior Plc said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 20, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Indivior plans cheaper opioid addiction drug if rivals launch copycats
Indivior Plc said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug. (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Indivior plans cheaper opioid addiction drug to keep copycats at bay
Indivior Plc said it will launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, as it seeks to claw back market share lost to copycat versions of the drug. (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Buprenorphine-Naloxone Cost-Effective for Opioid Use Disorder
MONDAY, Dec. 17, 2018 -- Buprenorphine-naloxone is cost-effective compared with extended-release naltrexone for treating opioid use disorder, according to a study published online Dec. 18 in the Annals of Internal Medicine. Sean M. Murphy, Ph.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2018 Category: Pharmaceuticals Source Type: news

Indivior wins fresh hold on Dr. Reddy's Suboxone copy
Indivior Plc has secured another hold on the launch of a generic competitor to its best-selling opioid addiction drug in the United States, the London-listed company said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - December 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Indivior says wins fresh hold on Suboxone copy
Indivior Plc said on Wednesday a U.S. court ruling had put a hold on Indian rival Dr. Reddy's Laboratories launching a generic competitor to the London-listed drugmaker's bestselling opioid addiction treatment. (Source: Reuters: Health)
Source: Reuters: Health - December 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

A Promising Way to Help Drug Users Is ‘Severely Lacking’ Around the World, Report Says
Global funding for harm reduction programs is in “crisis,” according to the latest Global State of Harm Reduction report, potentially threatening the effectiveness of HIV, hepatitis and drug overdose relief programs worldwide. Harm reduction policies and programs are meant to curb the negative effects associated with illicit drug use — such as overdoses and the spread of blood-borne illnesses like HIV and hepatitis C — rather than focusing solely on stopping substance use. Proponents, and plenty of research, suggest these practices can have a sizable impact on public health, and help drug users who ...
Source: TIME: Health - December 11, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime HIV/AIDS public health Source Type: news

The Treatment Gap: This City ’ s Overdose Deaths Have Plunged. Can Others Learn From It?
Dayton, Ohio, had one of the highest overdose death rates in the nation in 2017. The city made many changes, and fatal overdoses are down more than 50 percent from last year. (Source: NYT Health)
Source: NYT Health - November 25, 2018 Category: Consumer Health News Authors: ABBY GOODNOUGH Tags: Drug Abuse and Traffic Opioids and Opiates Addiction (Psychology) Deaths (Fatalities) Buprenorphine (Drug) Fentanyl Medicaid Naloxone (Drug) Dayton (Ohio) carfentanil Source Type: news

Dr. Reddy ’s notches win for generic Suboxone sublingual film
Shares in Dr. Reddy’s Laboratories (NYSE:RDY) shot up yesterday after the U.S. Court of Appeals for the Federal Circuit vacated a previous decision that blocked the company from selling a generic verson of Indivior‘s (LON:INDV) Suboxone buprenorphine and naloxone sublingual film. Dr. Reddy’s said it plans to resume launch activities for the product, which won FDA approvalin June. Get the full story at our sister site, Drug Delivery Business News. The post Dr. Reddy’s notches win for generic Suboxone sublingual film appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 21, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Pharmaceuticals Wall Street Beat Dr. Reddy's Laboratories indivior Source Type: news

U.S. court allows generic version of Indivior opioid abuse drug
A U.S. appeals court on Tuesday allowed generic drug company Dr. Reddy's Laboratories to sell a copycat version of the Indivior Plc opioid treatment Suboxone Film, sending Indivior's stock price down more than 40 percent. (Source: Reuters: Health)
Source: Reuters: Health - November 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Ohio medical practice reveals expansion plan
BrightView Health has opened an outpatient treatment facility in Chillicothe, and the Cincinnati-based medical practice intends to open similar addiction treatment centers in at least five more Ohio cities. Founded in 2014 in Norwood and now based in Walnut Hills, BrightView has four Greater Cincinnati locations plus one in Dayton and the new center in Chillicothe.  BrightView, which cares for people battling drug or alcohol addictions, focuses on medication assisted treatment such as Suboxone,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 19, 2018 Category: American Health Authors: Barrett J. Brunsman Source Type: news

EXCLUSIVE: Cincinnati medical practice reveals expansion plan
BrightView Health has opened an outpatient treatment facility in Chillicothe, and the Cincinnati-based medical practice intends to open similar addiction treatment centers in at least five more Ohio cities. Founded in 2014 in Norwood and now based in Walnut Hills, BrightView has four Greater Cincinnati locations plus one in Dayton and the new center in Chillicothe.  BrightView, which cares for people battling drug or alcohol addictions, focuses on medication assisted treatment such as Suboxone,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - November 14, 2018 Category: Health Management Authors: Barrett J. Brunsman Source Type: news

EXCLUSIVE: Cincinnati medical practice reveals expansion plan
BrightView Health has opened an outpatient treatment facility in Chillicothe, and the Cincinnati-based medical practice intends to open similar addiction treatment centers in at least five more Ohio cities. Founded in 2014 in Norwood and now based in Walnut Hills, BrightView has four Greater Cincinnati locations plus one in Dayton and the new center in Chillicothe.  BrightView, which cares for people battling drug or alcohol addictions, focuses on medication assisted treatment such as Suboxone,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 14, 2018 Category: Biotechnology Authors: Barrett J. Brunsman Source Type: news

Addiction Treatment Gap Is Driving A Black Market For Suboxone
This medicine to treat opioid addiction is hard to come by — only a fraction of doctors are approved to prescribe it. So some people trying to quit a heroin habit turn to a black market for help.(Image credit: Craig F. Walker/The Boston Globe/Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - October 5, 2018 Category: Consumer Health News Authors: Jake Harper Source Type: news

Cassipa (Buprenorphine and Naloxone Sublingual Film) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 19, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Treatment for Opioid Dependence
MONDAY, Sept. 10, 2018 -- Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the U.S. Food and Drug Administration said in a news release. Both buprenorphine and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2018 Category: Pharmaceuticals Source Type: news

Cassipa Approved for Opioid Dependence
MONDAY, Sept. 10, 2018 -- Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the agency said in a news release. Both buprenorphine and naloxone have been approved... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 10, 2018 Category: General Medicine Source Type: news

Teva wins FDA nod for sublingual film to treat opioid dependence
The FDA last week approved Teva Pharmaceuticals’ Cassipa buprenorphine and naloxone sublingual film as a maintenance treatment for opioid dependence. There are a number of brand name and generic versions of buprenorphine and naloxone therapies that are delivered via a sublingual film. Teva’s product contains 16 milligrams buprenorphine and 4 milligrams of naloxone, bringing a new dosage strength to the market. Get the full story at our sister site, Drug Delivery Business News. The post Teva wins FDA nod for sublingual film to treat opioid dependence appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Teva Pharmaceuticals Source Type: news

FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
FDA approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 7, 2018 Category: American Health Source Type: news

FDA Approves Cassipa (buprenorphine and naloxone) Sublingual Film as Maintenance Treatment for Opioid Dependence
September 7, 2018 -- The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. This action provides a new dosage strength... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 7, 2018 Category: Drugs & Pharmacology Source Type: news

Buprenorphine/Naloxone Rx Fills Up With Medicaid Expansion
TUESDAY, Aug. 28, 2018 -- There was an increase in buprenorphine with naloxone fills in expansion versus nonexpansion counties after Medicaid expansion, according to a study published online Aug. 17 in JAMA Network Open. Brendan Saloner, Ph.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 28, 2018 Category: Pharmaceuticals Source Type: news

Prescriptions for opioid use disorder treatment, opioid pain relievers after ACA Medicaid expansion
(JAMA Network) Medicaid expansion under the Affordable Care Act (ACA) was associated with an overall increase   in people filling prescriptions for buprenorphine with naloxone, which is a treatment for opioid use disorder, as well as an increase in people filling prescriptions for opioid pain relievers (OPRs) paid for by Medicaid in a data analysis from five states. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 17, 2018 Category: International Medicine & Public Health Source Type: news

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone
The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone. (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. Court Expedites Appeal to Re-Launch Generic Opioid Addiction Drug U.S. Court Expedites Appeal to Re-Launch Generic Opioid Addiction Drug
Indivior said on Monday a U.S. Court expedited a generic rival's appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker's blockbuster opioid addiction treatment, Suboxone Film (buprenorphine and naloxone).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 1, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

The Satisfaction of Suboxone Treatment
(MedPage Today) -- It's become the most comprehensive, integrated thing that I do (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 20, 2018 Category: Psychiatry Source Type: news

When an Iowa Family Doctor Takes On the Opioid Epidemic
Few primary care doctors are willing to do what Nicole Gastala has: endure the challenges of prescribing buprenorphine, a medication for opioid addiction. (Source: NYT Health)
Source: NYT Health - June 23, 2018 Category: Consumer Health News Authors: ABBY GOODNOUGH Tags: Buprenorphine (Drug) Opioids and Opiates Addiction (Psychology) Pain-Relieving Drugs Heroin Doctors Iowa Dr. Nicole Gastala suboxone Source Type: news

After Opioid Overdose, Only 30% Get Medicine to Treat Addiction After Opioid Overdose, Only 30% Get Medicine to Treat Addiction
Patients revived from an opioid overdose who get methadone or Suboxone treatment for addiction afterward are much more likely to be alive a year later, says a study published in the Annals of Internal Medicine.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

FDA approves first generic Suboxone
Mylan and Dr. Reddy's Laboratories have both received FDA approval to make the first generic versions of a Suboxone under-the-tongue film for the treatment of opioid addiction. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 18, 2018 Category: Pharmaceuticals Source Type: news

Dr Reddy's gets temporary restraining order on sale of generic Suboxone film in US
Dr Reddy's said in a BSE filing that the company remains confident in its legal positions on this patent. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 16, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves First Generic Under-the-Tongue Suboxone
FRIDAY, June 15, 2018 -- The first generic version of an under-the-tongue film to treat opioid addiction has been approved by the U.S. Food and Drug Administration. The generic version of Suboxone (buprenorphine and naloxone) film from Mylan... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 15, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first generic sublingual film to treat opioid addiction
The FDA this week approved the first generic version of Indivior‘s (LON:INDV) billion-dollar opioid addiction treatment, Suboxone. The generic buprenorphine and naloxone sublingual film, sold by Dr. Reddy’s Laboratories (NYSE:RDY) and Mylan (NSDQ:MYL), is designed to suppress withdrawal symptoms that crop in people addicted to opioids, as well as block the neurochemical effects of opioids. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves first generic sublingual film to treat opioid addiction appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 15, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Wall Street Beat Dr. Reddy's Laboratories indivior Mylan Source Type: news

Indivior shares dive after Dr Reddy's gets FDA approval for generic
(Reuters) - Britain's Indivior fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Dr Reddy's Laboratories gets USFDA nod for generic version of Suboxone
The company, which is launching the product in the US, said approval has been granted in the strengths of 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 15, 2018 Category: Pharmaceuticals Source Type: news

FDA Clears First Generic Versions of Suboxone Sublingual Film FDA Clears First Generic Versions of Suboxone Sublingual Film
Generic buprenorphine and naloxone sublingual film may increase access to treatment for opioid dependence, the agency said.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2018 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news